News & Presentations
Umoja Biopharma, Inc. announced today Clay B. Siegall, Ph.D. agreed to the Company’s request to resign from Umoja’s board of directors, effective immediately.
READ MORE >
SEATTLE, May 4, 2022 – Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with solid and hematologic malignancies, announced today that it will have an oral presentation at the International Society for Cell
READ MORE >
The Phase 1 clinical trial will evaluate UB-TT170 in osteosarcoma and follows the recent approval of Umoja’s first IND application by the FDA.
READ MORE >
SEATTLE, May 2, 2022 – Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells in vivo for patients with solid and hematologic malignancies, announced today that it will have an oral presentation and two posters at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, to be held May 16-19, 2022.
READ MORE >
SEATTLE, April 8, 2022 (GLOBE NEWSWIRE) – Umoja Biopharma, Inc., an oncology company leveraging its proprietary integrated technologies to create next-generation off-the-shelf in vivo (VivoVec) and induced pluripotent stem cell (iPSC) based immunotherapies for the treatment of solid tumors and hematologic malignancies, announced today the presentation of data supporting the use of a synthetic cytokine receptor, the Rapamycin Activated Cytokine Receptor (RACR), to derive synthetic innate lymphoid cells, RACR-induced cytotoxic innate lymphoid cells (RACR-iCILs).
READ MORE >